Autophagy Modulation by Antidepressants: Mechanisms and Implications

Depression is a significant global health concern that extends beyond mere neurotransmitter imbalances, as the significance of autophagy in cellular recycling is increasingly recognized as pivotal in its pathogenesis and therapeutic intervention. This review thoroughly integrates the insights on how various antidepressants, such as SSRIs, SNRIs, and TCAs, confer therapeutic efficacy through modulation of autophagy pathways. We present evidence indicating that these pharmacological agents can augment autophagic flux, facilitate the clearance of neurotoxic protein aggregates, mitigate neuroinflammation, and enhance mitochondrial functionality, all of which represent critical elements of depressive pathology. While acknowledging the context-dependent effects across varying neuronal populations and phases of the disorder, we delineate promising therapeutic targets within the autophagy framework (e.g., ULK1/Beclin-1 initiation complex, TFEB-mediated lysosomal biogenesis). Furthermore, we confront existing translational challenges, underscoring the necessity for insights that are specific to distinct cell types and clinically pertinent biomarkers of autophagy. This review promotes a paradigm shift towards precision psychiatry, accentuating the significance of individualized treatment strategies informed by autophagy profiling. By linking foundational mechanistic insights, we establish targeted autophagy modulation as a revolutionary pathway for developing more effective and personalized interventions for depressive disorders.